Connect
← Return to Is there any successful story?
Discussion
Is there any successful story?
MAC & Bronchiectasis | Last Active: Feb 6 8:02pm | Replies (78)Comment receiving replies
If you were to pay out of pocket for Arikayce it would set you back $15,000 a month. I found this out when my secondary insurance changed and they were denying me the Arikayce I had been on for 7 months. Fortunately my doctor got it straightened out by writing a pre-authorization but it was a hassle. So, bottom line is, I doubt that insurance wants to fork out that kind of money if the cheap stuff works. Always comes down to money, doesn't it?
Replies to "If you were to pay out of pocket for Arikayce it would set you back $15,000..."
Connect
Yes, follow the money!
In Wall Street News. Insmed is hoping to be what Dupixent is to asthma, or in their case what Brensocatib is to bronchiectasis. It will be the first ever pharmaceutical for bronchiectasis. A novel drug not just a change in molecule from an existing drug. Also makers of Arikayce.
Insmed issues preliminary revenue results, guidance for Arikayce
Insmed (NASDAQ:INSM) reported preliminary 2024 revenue results for its drug Arikayce and issued 2025 revenue guidance.
The drugmaker said 2024 revenue for Arikayce was approximately $363.7M, which exceeded the upper end of the company's guidance range. For 2025, Insmed (NASDAQ:INSM) is expecting global Arikayce revenue of $405M to $425M.
The drug developer said it also anticipates launching its drug brensocatib for the treatment of bronchiectasis in Q3 2025, pending FDA approval and the granting of priority review.
Insmed also now expects to report topline Phase 2 data for TPIP in patients with pulmonary arterial hypertension in mid-2025.
Topline data from a Phase 3 study of Arikayce in the treatment of MAC lung disease is expected in Q1 2026, while dosing in a study of its gene therapy INS1201 for Duchenne muscular dystrophy is expected to begin in the first half of 2025, according to a statement.